Aquestive Therapeutics, Inc.

NASDAQ:AQST

Drug Manufacturers - Specialty & Generic

Healthcare
$3.78 +5.08%

+$0.23 today

Market cap
$475.10M
Beta
1.45
P/E (TTM)
-8.3
EPS (TTM)
-$0.56
52W Low $2.93High $7.55

Volume 1.80M

Average 1.51M

AQST EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Aquestive Therapeutics, Inc.NASDAQ: AQST

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$4M, compared with -$18.51M a year earlier. Trailing-twelve-month EBITDA was -$51.63M.

Context

  • EBITDA amounted to 148.4% of revenue in FY2025, up 102.2 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 6 analysts of -$43.99M (+33.5%) for the fiscal year ending Dec 2026, a step up from the -148.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4M+85.4% QoQ
Last fiscal yearDec 2025
-$66.13M-148.4% YoY
LTMMar 2026
-$51.63M-40.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+78.4%-0.8%-79.2 pp
1 year-148.4%+33.5%+181.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(66.13M) USD
Year-over-year change
-148.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How AQST compares with its peers on the latest reported figures

  • AQST's LTM Mar 2026 EBITDA of -$51.63M is the 9th highest of the 10 companies compared; the peer median is $46.13M.
  • Its year-over-year change of -40.6% is the 6th highest of 10, against a peer median of -26.2%.
  • EBITDA amounts to 102.7% of revenue for AQST, versus a peer median of 14.7%.
AQST Competitors Peer median
EBITDA for AQST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$609.91M +83.3%+32.3%76.6%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$191.41M -26.2%+13.3%26.6%
ALKSAlkermes plcLTM Sep 2026$178.67M -59.0%+76.9%10.2%
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$140.47M +332.9%—114.9%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$46.13M +1163.1%—14.7%
DERMJourney Medical CorporationLTM Mar 2026-$1.44M -0.6%—2.2%
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026-$1.82M -156.1%+107.1%4.3%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026-$15.87M -109.6%-34.8%1.9%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-$51.63M -40.6%—102.7%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026-$136.24M -213.5%—62.6%
Peer median (excluding AQST) $46.13M-26.2%+32.3%14.7%

Competitors are the stored peer set for AQST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue50.83M47.68M50.58M57.56M44.55M
Cost of Revenue14.99M19.39M20.83M17.87M17.15M
Gross Profit35.84M28.29M29.75M39.69M27.39M
Gross Margin70.5%59.3%58.8%69.0%61.5%
Research & Development17.05M17.48M13.1M20.28M17.19M
Selling, General & Admin53.48M52.88M31.75M50.18M79.85M
Operating Expenses70.52M70.36M44.85M70.46M97.04M
Depreciation & Amortization2.96M2.39M1.35M718K559K
EBITDA(45.11M)(39.58M)1.18M(26.62M)(66.13M)
EBITDA Margin-88.8%-83.0%2.3%-46.2%-148.4%
Operating Income(34.68M)(42.07M)(15.1M)(30.77M)(69.65M)
Operating Margin-68.2%-88.2%-29.9%-53.5%-156.4%
Interest Income423K99K16.32M3.44M0
Interest Expense22.46M12.44M7.46M16.82M17.1M
Other Income / Expenses(35.86M)(12.34M)7.48M(13.38M)(14.13M)
Income Before Tax(70.54M)(54.41M)(7.63M)(44.15M)(83.78M)
Pre-Tax Margin-138.8%-114.1%-15.1%-76.7%-188.1%
Income Tax Expense00245K(14K)0
Net Income(70.54M)(54.41M)(7.87M)(44.14M)(83.78M)
Net Margin-138.8%-114.1%-15.6%-76.7%-188.1%
EPS (Basic)(1.85)(1.12)(0.13)(0.51)(0.76)
EPS (Diluted)(1.85)(1.12)(0.13)(0.51)(0.76)
Weighted Avg Shares38.08M48.73M61.26M86.73M121.97M
Weighted Avg Shares (Diluted)38.08M48.73M61.26M86.73M121.97M

Aquestive Therapeutics, Inc.

NASDAQ:AQST

Intrinsic Alpha fair value

Locked

Current Price

$3.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.